Retrospective Study
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 7, 2014; 20(45): 17120-17126
Published online Dec 7, 2014. doi: 10.3748/wjg.v20.i45.17120
Table 1 Demographic data of familial inflammatory bowel disease and sporadic inflammatory bowel disease
PhenotypeFamilial CD (n = 17)Sporadic CD (n = 51)P valueFamilial UC (n = 27)Sporadic UC (n = 81)P value
Sex> 0.999> 0.999
Male14 (82.4)42 (82.4)15 (55.6)45 (55.6)
Female3 (17.6)9 (17.6)12 (44.4)36 (44.4)
Age at diagnosis28.2 ± 10.329.2 ± 10.50.74236.2 ± 14.736.4 ± 12.80.951
≤ 16 yr (A1)0 (0)0 (0)0.8490 (0)0 (0)> 0.999
17-40 yr (A2)14 (82.4)43 (84.3)13 (48.1)39 (48.1)
> 40 yr (A3)3 (17.6)8 (15.7)14 (51.9)42 (51.9)
Age at symptom onset, yr22.6 ± 9.523.5 ± 9.30.43836.2 ± 14.536.7 ± 12.70.710
Main symptom at diagnosis
Abdominal pain10 (58.8)32 (62.7)0.7735 (18.5)30 (37.0)0.098
Diarrhea5 (29.4)16 (31.4)0.88011 (40.7)22 (27.2)0.232
Weight loss0 (0.0)2 (3.9)> 0.9990 (0.0)0 (0.0)> 0.999
Fever0 (0.0)1 (2.0)> 0.9990 (0.0)0 (0.0)> 0.999
Abdominal mass0 (0.0)0 (0.0)> 0.9990 (0.0)0 (0.0)> 0.999
Hematochezia2 (11.8)9 (17.6)0.71821 (77.8)66 (81.5)0.780
EIM031019
Somatitis0 (0.0)0 (0.0)> 0.9990 (0.0)2 (2.5)0.061
Arthritis and arthralgia0 (0.0)2 (4.2)> 0.9991 (3.7)8 (9.9)0.445
Erythema nodosum0 (0.0)1 (2.1)> 0.9994 (14.8)5 (6.2)0.223
Episcleritis0 (0.0)0 (0.0)> 0.9995 (18.5)4 (4.9)0.042
Table 2 Comparison of location/extent and behavior of disease between familial and sporadic inflammatory bowel disease using the Montreal classification n (%)
Type of IBDFamilial CD (n = 17)Sporadic CD (n = 51)P valueFamilial UC (n = 27)Sporadic UC (n = 81)P value
Location/extent1
13 (17.6)11 (21.6)> 0.99911 (40.7)28 (34.6)0.645
22 (11.8)9 (17.6)0.71815 (55.5)47 (58.0)0.826
312 (70.6)31 (60.8)0.5681 (3.8)6 (7.4)0.677
40 (0.0)0 (0.0)> 0.999
CD behavior20.668
19 (52.9)33 (64.7)0.391
23 (17.6)8 (15.7)> 0.999
35 (29.5)10 (19.6)0.504
Perianal fistula4 (23.5)12 (23.5)> 0.999
Table 3 Comparison of clinical characteristics between familial and sporadic inflammatory bowel disease n (%)
Familial CD (n = 17)Sporadic CD (n = 51)P valueFamilial UC (n = 27)Sporadic UC (n = 81)P value
Disease activity (at diagnosis)CDAIMayo score
Mean ± SD120.5 ± 68.2107.8 ± 82.10.2073.6 ± 2.03.7 ± 1.80.673
< 15011 (64.7)36 (70.6)0.7610-2, 9 (33.3)18 (22.2)0.428
150 ≤ and < 2204 (23.5)8 (15.7)3-5, 14 (51.9)52 (64.2)
≥ 2202 (11.8)7 (13.7)6-12, 4 (14.8)11 (13.6)
No. of hospitalizations0.1750.794
09 (52.9)35 (68.6)25 (92.6)73 (90.1)
1-26 (35.2)14 (27.5)1 (3.7)7 (8.7)
≥ 32 (11.7)2 (3.9)1 (3.7)1 (1.2)
No. of relapses0.3420.333
013 (76.5)44 (86.3)2272
1-24 (23.5)7 (13.7)59
≥ 30 (0.0)0 (0.0)00
Relapse duration after diagnosis, mo49.3 ± 65.538.9 ± 44.50.90758.2 ± 102.221.3 ± 20.50.898
Follow-up duration after diagnosis, mo84 (24-312)36 (8-240)0.00896 (12-240)60 (12-85)0.170
Table 4 Comparison of number of bowel resection surgeries between familial and sporadic inflammatory bowel disease n (%)
PhenotypeFamilial CD (n = 17)Sporadic CD (n = 51)P valueFamilial UC (n = 27)Sporadic UC (n = 81)P value
Number of surgeries0.1940.759
013 (76.5)44 (86.3)27 (100)79 (97.5)
13 (17.6)7 (13.7)0 (0.0)2 (2.5)
21 (5.9)0 (0.0)0 (0.0)0 (0.0)
Table 5 Medication types and adverse events in patients with familial and sporadic inflammatory bowel disease n (%)
Familial CD (n = 17)Sporadic CD (n = 51)P valueFamilial UC (n = 27)Sporadic UC (n = 81)P value
5-ASA16 (94.1)50 (98.0)> 0.99917 (63.0)64 (79.0)0.124
Steroid7 (41.2)15 (29.4)0.5515 (18.5)18 (22.2)0.684
Thiopurines7 (41.2)28 (54.9)0.4065 (18.5)11 (13.6)0.540
Anti-TNF antibodies3 (17.6)0 (0.0)0.0140 (0.0)0 (0.0)-
Suppository
5-ASA1 (5.9)00.2503 (11.1)1 (1.2)0.047
Steroid02 (3.9)> 0.99918 (66.7)35 (43.2)0.035
AEs by thiopurine4 (23.5)8 (15.7)0.4771 (3.7)6 (7.4)0.677
Leukopenia4 (23.5)7 (13.7)0.4481 (3.7)4 (4.9)> 0.999
Nausea01 (2.0)> 0.9990 (0.0)0 (0.0)> 0.999
Arthralgia00> 0.9990 (0.0)1 (1.2)> 0.999
Skin lesion00> 0.9990 (0.0)1 (1.2)> 0.999
Pancreatitis00> 0.99900> 0.999
Elevation of liver enzyme00> 0.99900> 0.999